STOCK TITAN

Armistice Capital discloses 602,965-share, 9.99% stake in INVO Fertility (IVF)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

INVO Fertility, Inc. ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 602,965 shares of common stock, representing 9.99% of the class as of 12/31/2025. The filing states Armistice Capital exercises shared voting and dispositive power over these shares.

The schedule explains the shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager; Mr. Boyd is managing member of Armistice Capital. The Master Fund is identified as the direct holder and has the right to receive dividends or sale proceeds.

Positive

  • None.

Negative

  • None.

Insights

Armistice Capital reports a 9.99% stake (602,965 shares) in INVO Fertility as of 12/31/2025.

Armistice Capital is disclosed as investment manager of the Master Fund, which the filing identifies as the direct holder of the shares. The report attributes shared voting and shared dispositive power of 602,965 shares to Armistice Capital and Mr. Boyd.

Holder structure and rights: the Master Fund "has the right to receive dividends from, or the proceeds from the sale of" the shares. Timing: the ownership stake is stated with an as of 12/31/2025 anchor. Cash‑flow treatment is described as the Master Fund holding rights to dividends/proceeds.

The filing is a passive ownership disclosure under Schedule 13G with joint filing language.

The statement includes a joint filing agreement and explains that Armistice Capital exercises voting and investment authority under an Investment Management Agreement; Mr. Boyd is cited as managing member, which explains shared powers rather than sole control.

Implications: the filing documents a near‑10% passive stake and clarifies attribution. Subsequent amendments or changes in voting/dispositive status would be material; timing not specified beyond the 12/31/2025 ownership date.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in INVO Fertility (IVF)?

Armistice Capital and Steven Boyd report beneficial ownership of 602,965 shares, equal to 9.99% of INVO Fertility's common stock as of 12/31/2025. The shares are held directly by Armistice Capital Master Fund Ltd., per the filing.

Who holds voting and dispositive power over the reported IVF shares?

The filing attributes shared voting power and shared dispositive power of 602,965 shares to Armistice Capital and Steven Boyd. Armistice Capital, as investment manager, exercises voting and investment authority over the Master Fund's holdings.

Does the Schedule 13G identify the direct holder of the IVF shares?

Yes. The filing names Armistice Capital Master Fund Ltd. as the direct holder of the reported shares, with Armistice Capital acting as the Master Fund's investment manager under an Investment Management Agreement.

Are dividends or sale proceeds for the IVF shares assigned to another party?

The Master Fund is stated to "have the right to receive dividends from, or the proceeds from the sale of" the reported securities. This identifies the Master Fund as entitled to cash flows from these shares.
INVO Fertility, Inc

NASDAQ:IVF

IVF Rankings

IVF Latest News

IVF Latest SEC Filings

IVF Stock Data

7.10M
6.88M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SARASOTA